van Weelden Wenneke, Wekker Vincent, de Wit Leon, Limpens Jacqueline, Ijäs Hilkka, van Wassenaer-Leemhuis Aleid G, Roseboom Tessa J, van Rijn Bas B, DeVries J Hans, Painter Rebecca C
Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.
Diabetes Ther. 2018 Oct;9(5):1811-1829. doi: 10.1007/s13300-018-0479-0. Epub 2018 Aug 30.
Antidiabetic drugs (OADs) are increasingly prescribed to treat hyperglycaemia during pregnancy in women with gestational diabetes mellitus (GDM) or polycystic ovary syndrome (PCOS), even though long-term effects on offspring are unknown. This systematic review summarises the evidence of follow-up studies of randomised controlled trials (RCTs) reporting on long-term effects of prenatal exposure to OADs on offspring.
The MEDLINE, EMBASE and CENTRAL databases were searched from inception to April 2018 for the concepts antidiabetic agents and prenatal exposure (or pregnancy and offspring/child) in combination with an RCT search filter. RCTs evaluating post-neonatal health effects in offspring and comparing maternal treatment with an OAD with no treatment, placebo, an alternative OAD or insulin during pregnancy were eligible for inclusion. Two independent researchers selected, extracted and assessed the data. Meta-analyses were performed using a random effects model and the Cochrane Collaboration's risk of bias tool was used for quality assessment.
Ten studies were included, with a maximal follow-up duration of 9 years, comprising 778 children of mothers with GDM or PCOS who were randomised to either metformin or insulin/placebo during pregnancy. Meta-analysis showed that children prenatally exposed to metformin were heavier compared to controls (standardised mean difference (SMD) 0.26 [95% CI 0.11-0.41]), but not taller (SMD 0.10 [95% CI -0.14-0.33]). Additionally, offspring body mass index (BMI) z scores did not differ according to metformin exposure (mean difference 0.30 [95% CI -0.01-0.61]). Individual small studies reported that prenatal exposure to metformin was associated with greater mid-upper arm, head and waist circumferences, biceps skinfolds, waist-to-height ratio, more arm fat, higher fasting glucose, ferritin and lower LDL cholesterol in offspring.
Prenatal exposure to metformin is associated with increased offspring weight, but not with height or BMI. Larger follow-up studies are needed to confirm and look into the implications of these findings. Plain language summary available for this article.
抗糖尿病药物(OADs)越来越多地被用于治疗妊娠期糖尿病(GDM)或多囊卵巢综合征(PCOS)女性孕期的高血糖,尽管其对后代的长期影响尚不清楚。本系统评价总结了随机对照试验(RCTs)随访研究的证据,这些研究报告了产前暴露于OADs对后代的长期影响。
检索MEDLINE、EMBASE和CENTRAL数据库,从建库至2018年4月,检索抗糖尿病药物和产前暴露(或妊娠与后代/儿童)的概念,并结合RCT检索过滤器。评估后代新生儿期后健康影响且比较孕期母亲使用OAD治疗与未治疗、安慰剂、另一种OAD或胰岛素的RCT符合纳入标准。两名独立研究人员选择、提取和评估数据。采用随机效应模型进行荟萃分析,并使用Cochrane协作网偏倚风险工具进行质量评估。
纳入10项研究,最长随访时间为9年,包括778名GDM或PCOS母亲的子女,她们在孕期被随机分配接受二甲双胍或胰岛素/安慰剂治疗。荟萃分析显示,产前暴露于二甲双胍的儿童比对照组更重(标准化均数差(SMD)0.26 [95%CI 0.11 - 0.41]),但身高无差异(SMD 0.10 [95%CI -0.14 - 0.33])。此外,根据二甲双胍暴露情况,后代体重指数(BMI)z评分无差异(均数差0.30 [95%CI -0.01 - 0.61])。个别小型研究报告,产前暴露于二甲双胍与后代上臂中部、头部和腰围更大、肱二头肌皮褶厚度、腰高比、更多的手臂脂肪、更高的空腹血糖、铁蛋白以及更低的低密度脂蛋白胆固醇有关。
产前暴露于二甲双胍与后代体重增加有关,但与身高或BMI无关。需要更大规模的随访研究来证实并探讨这些发现的意义。本文提供通俗易懂的总结。